[ON HOLD] Anti-Zika Virus NS1 Protein Monoclonal Antibody and Rapid Diagnosis Device


This technology may be used to detect Zika virus infections without cross-reactivity from similar virus infections such as dengue or other flaviviruses.

Problem Addressed

Zika virus infections correlate with microcephaly and other serious neurological disorders. Accurate rapid diagnostics are critically needed to monitor patients, especially during pregnancy and to provide epidemiological surveillance. Zika and Dengue viruses co-circulate and share protein homologies, creating the potential for crossover detection problems, and complicating the development of specific diagnostics. There are currently no Zika virus antigen rapid tests. Existing Zika infection diagnosis methods involve Real Time RT-PCR which are time consuming and not widely available. Accurate, available, and inexpensive Zika rapid diagnostics are especially critical for pregnant women or women considering pregnancy.   


This invention comprises monoclonal antibody pairs that can identify Zika virus infection at high specificity. The target antigen is the NS1 glycoprotein. This invention includes a paperfluidic detection kit able to detect Zika virus infections in under 30 minutes and minimal input sample. Tissue extracts, bodily fluids, blood or derivatives or blood are suitable for diagnostic applications.


  • Novel monoclonal antibodies that detect Zika virus infection
  • Highly-specific antibodies can distinguish Zika viruses without cross-reactivity from Dengue virus or other flavivirus NS1proteins
  • Rapid diagnostic device detects Zika virus NS1 in thirty microliters of solution in under 30 minutes
  • These antibody pairs have been tested for accuracy and specificity on human samples
  • Low cost assays compatible for use in remote locations without complex equipment

Related Technologies

Thechnology # 18262 Anti-dengue Virus NS1 Protein Monoclonal Antibodies